Assessment for Long-Term Cardiovascular Impairment Associated with Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors
Trastuzumab (Herceptin) is a common treatment for patients with breast cancer that overexpresses the receptor for a protein called HER2. However, trastuzumab can impair heart function in some people. Heart function may be assessed using different methods.
The purpose of this study is to compare three different methods for assessing heart function: echocardiography (heart ultrasound) with "strain" (a new method of measuring heart function), exercise testing, and echocardiography after exercise. These tests will be used to assess heart function in three study groups: women who received trastuzumab for breast cancer and who experienced heart side effects; women treated for breast cancer with trastuzumab who did not have any heart side effects; and a third group of healthy volunteers without cancer.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have completed trastuzumab treatment for breast cancer (or another anti-HER2 treatment, such as lapatinib) two or more years before entering the study.
- This study is for women age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Anthony Yu at 212-639-7932.